Investigational drug · Phase 3
ACP-204
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Alzheimer's Disease Psychosis, Lewy Body Dementia Psychosis.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
4
Any phase or sponsor naming "ACP-204"
First trial start
2023
Nov 14, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ACP-204", any sponsor or status.
Conditions studied
As listed on its trial records.
- Alzheimer's Disease Psychosis
- Lewy Body Dementia Psychosis
Approved drugs for the same conditions: Alzheimer's disease · Neurology · Psychiatry
Largest trials
Live from ClinicalTrials.gov: studies naming "ACP-204" as an intervention, largest first.
- ACP-204 in Adults With Alzheimer's Disease PsychosisPivotal-lookingRecruiting
ACADIA Pharmaceuticals Inc.Industry
NCT06159673 · 1,074 participants (planned) · Start Nov 14, 2023 · Primary completion Jan 2028
Drug: ACP-204; Placebo · For: Alzheimer's Disease Psychosis
Sites: Chandler, Arizona; Scottsdale, Arizona; Anaheim, California · 155 sites in all
- ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension StudyPivotal-lookingEnrolling by invitation
ACADIA Pharmaceuticals Inc.Industry
NCT06194799 · 752 participants (planned) · Start Apr 23, 2024 · Primary completion Apr 2029
Drug: ACP-204 · For: Alzheimer's Disease Psychosis
Sites: Scottsdale, Arizona; Costa Mesa, California; Fresno, California · 78 sites in all
- Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia PsychosisPivotal-lookingRecruiting
ACADIA Pharmaceuticals Inc.Industry
NCT07029581 · 180 participants (planned) · Start Aug 6, 2025 · Primary completion Feb 2028
Drug: ACP-204; Placebo · For: Lewy Body Dementia Psychosis
Sites: Irvine, California; Aurora, Colorado; Washington D.C., District of Columbia · 62 sites in all
- Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia PsychosisPivotal-lookingRecruiting
ACADIA Pharmaceuticals Inc.Industry
NCT07095465 · 126 participants (planned) · Start Nov 14, 2025 · Primary completion Feb 2029
Drug: ACP-204 · For: Lewy Body Dementia Psychosis
Sites: Irvine, California; Washington D.C., District of Columbia; Aventura, Florida · 36 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- An Open-Label Study Investigating the 5-HT2A Receptor Occupancy of Remlifanserin (ACP-204) With the PET Radioligand [18F]Altanserin in Healthy Male Participants.
Burstein ES, Sandiego C, Raether B, et al. · Clin Pharmacol Drug Dev 2026
- Nonclinical Characterization of ACP-204, a Novel Selective 5-HT2A Receptor Inverse Agonist.
Burstein ES, Olsson R, Skold N, et al. · J Pharmacol Exp Ther 2026
- Population pharmacokinetics of remlifanserin (ACP-204), a serotonin 2A receptor inverse agonist.
Darwish M, Lin N, Dirks B, et al. · Alzheimers Dement (N Y) 2026
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.